Accelerated approval is supported by 34-week interim data from the phase 3 I CAN trial showing a statistically significant 43% placebo-adjusted reduction in proteinuria.
The new 150mg oral pellet formulation provides a capsule-free prophylactic option for adults and adolescents with hereditary ...
Enzyme-inducing ASDs increase risk for incident osteoporosis or osteopenia, but few patients receive vitamin D supplementation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results